Introduction {#section1-2055102915612271}
============

Multiple sclerosis (MS) is a chronic, progressive, auto-immune disease that affects the central nervous system ([@bibr23-2055102915612271]). About 2.5 million people worldwide have MS, it is one of the most common neurological disorders and cause of disability of young adults ([@bibr54-2055102915612271]). Although the etiology is unknown, MS is a complex disease that probably involves multiple genes and environmental factors. The most widely studied environmental factors include vitamin D deficiency ([@bibr34-2055102915612271]), Epstein--Barr virus ([@bibr5-2055102915612271]), and stress ([@bibr4-2055102915612271]).

Stress is the factor that has generated the most controversial results. Some studies report an association between stress and MS ([@bibr9-2055102915612271]; [@bibr31-2055102915612271]; [@bibr51-2055102915612271]) but others failed to find this association or only found a quasi-significant relationship ([@bibr14-2055102915612271]; [@bibr46-2055102915612271]). These disparate results can be explained by heterogeneity in study design ([@bibr4-2055102915612271]) as well as by the indirect way stress affects MS through other variables ([@bibr32-2055102915612271]). Factors proposed as potential moderators and mediators between stress and MS include stressor properties, environmental factors, and patients' biological, social, and psychological characteristics ([@bibr32-2055102915612271]).

Some studies have reviewed articles published on the relationship between stress and MS. In 1999, the American Academy of Neurology found class II evidence both for and against an association between stress and the onset or exacerbation of MS, concluding that a relationship between MS and psychological stress was possible but data were insufficient for reasonable medical certainty ([@bibr17-2055102915612271]). In 2004, Mohr et al. analyzed 14 studies and found a consistent association between stressful life events and subsequent exacerbation in MS. Finally, in a recent systematic review, [@bibr4-2055102915612271] found that 15 of 17 studies reported a significant stress--MS relationship; however, they pointed out that the heterogeneity in the measurement of stress precluded secure conclusions. Other authors highlight the need to identify factors that might modify the stress--MS association ([@bibr1-2055102915612271]; [@bibr8-2055102915612271]). All these reviews focused on the quality and main results of the studies, but none examined the results in function of the way stress was measured or of potential moderators and mediators.

This study aims to review the evidence on the association between stress and MS, focusing on the methods used to evaluate whether stress affects MS and the role of potential moderator and mediator factors on this association. This knowledge can be useful for the design of future studies and for developing better interventions in MS patients.

Methods {#section2-2055102915612271}
=======

Literature search {#section3-2055102915612271}
-----------------

We searched the Web of Knowledge (MEDLINE and Web of Science), Scopus, and PsycINFO databases for relevant articles published from 1900 through December 2014. We searched for the terms *stress\** AND *multiple sclerosis*. To obtain additional eligible articles, we also examined the reference lists of the articles located.

Selection criteria {#section4-2055102915612271}
------------------

We selected articles that met the following inclusion criteria: (1) published in international peer-reviewed academic journals (book chapters, abstracts of conference proceedings, and dissertations were excluded), (2) published in English or Spanish, (3) measuring psychosocial stress in everyday situations (induced stress studies were excluded), (4) evaluating MS onset, relapse rate during a period of time, or MS-related health status, and (5) observational and non-stress interventional studies in human subjects (stress-interventional and animal studies were excluded).

Two reviewers (L.B.B. and R.M.V.) independently selected articles and examined titles and abstracts to exclude those out-of-scopes. When the first two reviewers disagreed, three reviewers (L.B.B., R.M., and F.X.A.N.) reached a consensus about disagreements. Then, full papers were reviewed and selected for this study. All the processes were done following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements ([@bibr29-2055102915612271]).

The qualitative appraisal was based on Newcastle--Ottawa quality assessment scale recommended by the Cochrane Non-Randomized Studies Methods Working Group ([@bibr53-2055102915612271]), following the adaptation for stress and MS made by [@bibr4-2055102915612271].

Data extraction {#section5-2055102915612271}
---------------

We arranged papers into chronological order and extracted details on (1) source (authors, year, and country); (2) whether the study measured onset, relapse, or both; (3) design; (4) sample; (5) diagnostic criteria for MS, relapse, and health status; (6) study period; (7) qualitative assessment; (8) the instruments used to measure stress; (9) modifying factors considered; and (10) results regarding the relationship between stress and MS and influences of modifying factors.

Following [@bibr32-2055102915612271], we classified modifying factors according to the following criteria: the nature of the stressor; the environmental context; and the patient's biological, social, and psychological characteristics. We classified articles according to whether they evaluated disease onset or progression; however, we decided not to analyze disease type and process because the disease process cannot be controlled and almost all the papers reviewed dealt with remittent-recurrent or secondary-progressive clinical types.

Risk of bias {#section6-2055102915612271}
------------

Our approach carries a risk of different biases. First, the selection process is susceptible to publication bias. Second, there is a risk of excluding papers using different terms to refer to the same concepts, for example, disseminated sclerosis instead of MS or anxiety instead of stress. Third, we may have missed other potential modifying factors because we only analyze factors included in studies that first focused on the relationship between MS and stress.

Results {#section7-2055102915612271}
=======

Study selection {#section8-2055102915612271}
---------------

The initial database search provided 5030 records and we identified 11 records from other sources. After we removed duplicate studies and irrelevant titles, 336 unique and potentially relevant abstracts remained ([Figure 1](#fig1-2055102915612271){ref-type="fig"}). After excluding out-of-scope records, we checked the full texts of 212 records. We excluded 189 articles because they did not meet the inclusion criteria: 5 (2.6%) were not published in English or Spanish; 122 (64.6%) did not measure psychosocial stress in everyday situations; 53 (28%) did not evaluate MS onset, relapse rate, or health status; 2 (1.1%) were stress-interventional studies; and 7 (3.7%) were animal studies. Thus, 23 studies were included.

![Search and exclusion process.\
\*References of other papers.](10.1177_2055102915612271-fig1){#fig1-2055102915612271}

Characteristics of the studies {#section9-2055102915612271}
------------------------------

[Table 1](#table1-2055102915612271){ref-type="table"} reports the main characteristics of the selected papers. When we grouped papers according to whether they evaluated the effects of stress on onset or progression, we found 9 papers evaluating the effects of stress on onset ([@bibr18-2055102915612271]; [@bibr22-2055102915612271]; [@bibr26-2055102915612271]; [@bibr35-2055102915612271], [@bibr36-2055102915612271]; [@bibr40-2055102915612271]; [@bibr45-2055102915612271]; [@bibr46-2055102915612271]; [@bibr51-2055102915612271]) and 14 evaluating the effects on disease progression, of which 13 focused on relapses ([@bibr1-2055102915612271], [@bibr2-2055102915612271]; [@bibr7-2055102915612271], [@bibr8-2055102915612271]; [@bibr9-2055102915612271]; [@bibr14-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr31-2055102915612271], [@bibr32-2055102915612271]; [@bibr38-2055102915612271]; [@bibr44-2055102915612271]; [@bibr52-2055102915612271]) and 1 on health status ([@bibr48-2055102915612271]).

###### 

Main characteristics of papers selected (sorted by onset/relapse in chronological order).

![](10.1177_2055102915612271-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year, and country                                   Onset/relapse       Study design                             Sample                                         Diagnostic criteria   Relapse criteria                   Study period of time                                                             Quality assessment
  ----------------------------------------------------------- ------------------- ---------------------------------------- ---------------------------------------------- --------------------- ---------------------------------- -------------------------------------------------------------------------------- --------------------
  Papers measuring disease onset                                                                                                                                                                                                                                                                                    

   [@bibr45-2055102915612271], United Kingdom                 Onset and relapse   Case--control (retrospective)            *n* = 100 MS\                                  Not mentioned         Not mentioned                      Onset: unspecific time to onset\                                                 Selection: 3\
                                                                                                                           *n* = 100 controls (organic CNS diseases)\                                                              Relapse: since onset to interview                                                Comparability: 1\
                                                                                                                           (*n* = 50/50 females/males)                                                                                                                                                              Exposure: 1

   [@bibr26-2055102915612271], Israel/United States           Onset and relapse   Cross-sectional/cohort (retrospective)   *n* = 32 MS\                                   Not mentioned         Not mentioned                      Onset: unspecific time to onset\                                                 Selection: 1\
                                                                                                                           (*n* = 22 females/*n* = 10 males)                                                                       Relapse: since onset to interview                                                Comparability: 0\
                                                                                                                                                                                                                                                                                                                    Outcome: 1

   [@bibr51-2055102915612271], Canada                         Onset               Case--control (retrospective)            *n* = 100 MS\                                  Schumacher            Not mentioned                      Two years before onset                                                           Selection: 3\
                                                                                                                           *n* = 100 controls (rheumatology/neurology)\                                                                                                                                             Comparability: 1\
                                                                                                                           (females 2.3:1 males)                                                                                                                                                                    Exposure: 2

   [@bibr18-2055102915612271], United States/United Kingdom   Onset               Case--control (retrospective)            *n* = 39 MS\                                   Poser                 Not mentioned                      One year before onset                                                            Selection: 3\
                                                                                                                           *n* = 40 controls (healthy)\                                                                                                                                                             Comparability: 1\
                                                                                                                           (*n* = 29/30 females/*n* = 10 males)                                                                                                                                                     Exposure: 1

   [@bibr40-2055102915612271], Italy                          Onset               Case--control (retrospective)            *n* = 65 MS\                                   Not mentioned         Not mentioned                      One year before onset                                                            Selection: 1\
                                                                                                                           *n* = 27 controls (non-genetic chronic PNP)\                                                                                                                                             Comparability: 0\
                                                                                                                           (*n* = 40/12 females/*n* = 25/15 males)                                                                                                                                                  Exposure: 2

   [@bibr22-2055102915612271], China/United States            Onset               Case--control (retrospective)            *n* = 41 MS\                                   Poser                 Not mentioned                      Three years before onset                                                         Selection: 3\
                                                                                                                           *n* = 41 controls (healthy)\                                                                                                                                                             Comparability: 1\
                                                                                                                           (*n* = 26 females/*n* = 15 males)                                                                                                                                                        Exposure: 1

   [@bibr46-2055102915612271], Norway/United States           Onset               Cohort (prospective)                     *n*C1 = 121,700\                               Poser                 Not mentioned                      Follow-up 30 years                                                               Selection: 3\
                                                                                                                           *n*C2 = 116,671\                                                                                                                                                                         Comparability: 1\
                                                                                                                           (healthy female nurses)                                                                                                                                                                  Outcome: 3

   [@bibr35-2055102915612271], Denmark                        Onset               Cohort (prospective)                     *n*C3/*n*C4 = 30 million people\               McDonald              Not mentioned                      Follow-up 28 years                                                               Selection: 4\
                                                                                                                           (healthy people)                                                                                                                                                                         Comparability: 1\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr36-2055102915612271], Denmark                        Onset               Cohort (prospective)                     *n*C5 = 2.9 million people\                    McDonald              Not mentioned                      Follow-up 18 years                                                               Selection: 4\
                                                                                                                           (healthy people)                                                                                                                                                                         Comparability: 1\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

  Papers measuring disease progression                                                                                                                                                                                                                                                                              

   [@bibr52-2055102915612271], Canada                         Relapse             Case--control (retrospective)            *n* = 95 MS in exacerbation\                   Poser                 Clinical criteria^2^               Three months prior relapse (exacerbation group) or interview (remission group)   Selection: 4\
                                                                                                                           *n* = 95 MS in remission\                                                                                                                                                                Comparability: 1\
                                                                                                                           (2.3 females:1 males)                                                                                                                                                                    Exposure: 2

   [@bibr14-2055102915612271], Italy                          Relapse             Case--control (prospective)              *n* = 89 MS in exacerbation\                   Poser                 Clinical criteria^3^               Follow-up 1 year\                                                                Selection: 4\
                                                                                                                           *n* = 89 MS in remission\                                                                               3 months before exacerbation                                                     Comparability: 1\
                                                                                                                           (*n* = 62 females/*n* = 27 males)                                                                                                                                                        Exposure: 2

   [@bibr48-2055102915612271], United States                  Health status       Cohort (prospective)                     *n* = 101 MS\                                  Poser                 Not mentioned                      Follow-up 6 years                                                                Selection: 3\
                                                                                                                           *n* = 96 controls (healthy)\                                                                                                                                                             Comparability: 1\
                                                                                                                           (*n* = 75 females/*n* = 26/21 males)                                                                                                                                                     Outcome: 2

   [@bibr31-2055102915612271], United States                  Relapse             Cohort (prospective longitudinal)        *n* = 36 MS\                                   Poser                 Clinical criteria^4^\              Follow-up for 28--100 weeks                                                      Selection: 3\
                                                                                                                           (*n* = 22 females/*n* = 14 males)                                    New MRI Gd+ lesions                                                                                                 Comparability: 1\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr1-2055102915612271], United States                   Relapse             Cohort (prospective longitudinal)        *n* = 23 MS (females)                          Poser                 Clinical criteria^6^               Follow-up 1 year                                                                 Selection: 4\
                                                                                                                                                                                                                                                                                                                    Comparability: 0\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr32-2055102915612271], United States                  Relapse             Cohort (prospective longitudinal)        *n* = 36 MS\                                   Poser                 New MRI Gd+ lesions                Follow-up for 28--100 weeks                                                      Selection: 3\
                                                                                                                           (*n* = 22 females/*n* = 14 males)                                                                                                                                                        Comparability: 2\
                                                                                                                                                                                                                                                                                                                    Outcome: 2

   [@bibr2-2055102915612271], United States                   Relapse             Cohort (prospective longitudinal)        *n* = 50 MS (females)                          Poser                 Clinical criteria^6^               Follow-up 1 year                                                                 Selection: 4\
                                                                                                                                                                                                                                                                                                                    Comparability: 1\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr9-2055102915612271], The Netherlands                 Relapse             Cohort (prospective longitudinal)        *n* = 73 MS (*n* = 56 females/16 males)        Not mentioned         Clinical criteria^5^               Follow-up 1.4 years (average 74 weeks, range 8--120 weeks)                       Selection: 3\
                                                                                                                                                                                                                                                                                                                    Comparability: 1\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr7-2055102915612271], Australia                       Relapse             Cohort (prospective longitudinal)        *n* = 101 MS\                                  Poser                 Clinical criteria^6^               Follow-up 2 years                                                                Selection: 4\
                                                                                                                           (*n* = 81 females/*n* = 20 males)                                                                                                                                                        Comparability: 2\
                                                                                                                                                                                                                                                                                                                    Outcome: 2

   [@bibr8-2055102915612271], Australia                       Relapse             Cohort (prospective longitudinal)        *n* = 101 MS\                                  Poser                 Clinical criteria^6^               Follow-up 2 years                                                                Selection: 4\
                                                                                                                           (*n* = 81 females/*n* = 20 males)                                                                                                                                                        Comparability: 2\
                                                                                                                                                                                                                                                                                                                    Outcome: 2

   [@bibr27-2055102915612271], Greece                         Relapse             Cohort (prospective longitudinal)        *n* = 26 MS (females)                          McDonald              Clinical criteria^5^               Follow-up mean 56.3 weeks                                                        Selection: 4\
                                                                                                                                                                                                                                                                                                                    Comparability: 0\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr44-2055102915612271], Greece/France                  Relapse             Cohort (prospective longitudinal)        *n* = 37 MS (females)                          McDonald              Clinical criteria^5^               Follow-up 1 year                                                                 Selection: 3\
                                                                                                                                                                                                                                                                                                                    Comparability: 2\
                                                                                                                                                                                                                                                                                                                    Outcome: 3

   [@bibr28-2055102915612271], Greece                         Relapse             Cohort (prospective)                     *n* = 24 MS (SSRI)\                            McDonald              Clinical criteria^5^               Follow-up 1 year                                                                 Selection: 1\
                                                                                                                           *n* = 24 MS (no SSRI)\                                                                                                                                                                   Comparability: 1\
                                                                                                                           (females)                                                                                                                                                                                Outcome: 3

   [@bibr38-2055102915612271], Iran                           Relapse             Cohort (prospective)                     *n* = 57 MS patients\                          McDonald              Clinical criteria^1^ unspecified   Follow-up 1 year                                                                 Selection: 1\
                                                                                                                           (*n* = 46 females/*n* = 11 males)                                                                                                                                                        Comparability: 0\
                                                                                                                                                                                                                                                                                                                    Outcome: 3
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MS: multiple sclerosis; CNS: central nervous system; PNP: polyneuropathy; *n*C1: *n* cohort 1; *n*C2: *n* cohort 2; *n*C3: *n* cohort of persons who became parents between 1968 and 2010; *n*C4: *n* cohort of persons who married between 1968 and 2010; *n*C5: *n* cohort of people born from 1968 to 2011; MRI: magnetic resonance imaging; Gd+: gadolinium; SSRI: selective serotonin reuptake inhibitor (escitalopram); EDSS: Expanded Disability Status Scale.

Clinical criteria for relapses: 1. Unspecified. 2. Sudden appearance of a symptom typical of MS, which may have been new to participants or experienced during a previous relapse. Remission was defined as no symptoms in the previous 6 months. 3. New neurological symptom associated with a change of at least 1.0 point in EDSS which lasted more than 24 hours. 4. Increase of 1.0 point on the EDSS from the previous examination. 5. A worsening of existing symptoms or appearance of new symptoms, lasting more than 24 hours and after at least 30 days of improvement or stability not associated with fever. 6. Occurrence, recurrence, or worsening of symptom(s) of neurological dysfunction, associated with confirmatory change on neurological examination, lasted more than 48 hours, not associated with fever and occurred after at least 30 days of improvement or stability.

A wide variety of countries were represented, but nine (39%) were done in or in collaboration with the institutions in the United States.

Despite the broad range of years searched, all the papers selected were published after 1950. One paper was published in the 1950s, 1 in the 1970s, 2 in the 1980s, 4 in the 1990s, 10 in the 2000s, and 5 from 2010 to 2014.

The samples in the studies ranged from 23 to 170 participants with MS, with the exceptions of the three large cohort studies ([@bibr35-2055102915612271], [@bibr36-2055102915612271]; [@bibr46-2055102915612271]), which followed between 230,000 and 30 million people initially healthy participants. The control/comparison groups consisted of other individuals with MS in three studies ([@bibr14-2055102915612271]; [@bibr28-2055102915612271]; [@bibr52-2055102915612271]), of healthy individuals in three studies ([@bibr18-2055102915612271]; [@bibr22-2055102915612271]; [@bibr48-2055102915612271]), and of individuals with other diseases in three studies: organic diseases of the central nervous system ([@bibr45-2055102915612271]), rheumatologic/neurologic diseases ([@bibr51-2055102915612271]), and polyneuropathy ([@bibr40-2055102915612271]).

### Study design {#section10-2055102915612271}

Six of the nine studies examining the relationship between stress and the onset of MS were retrospective: one ([@bibr26-2055102915612271]) was cross-sectional and five ([@bibr18-2055102915612271]; [@bibr22-2055102915612271]; [@bibr40-2055102915612271]; [@bibr45-2055102915612271]; [@bibr51-2055102915612271]) case--control; these studies focused on a period from 1 to 3 years before onset or on an unspecific period of time before onset ([@bibr26-2055102915612271]; [@bibr45-2055102915612271]). Three prospective studies that examined the relationship between stress and the onset of MS were longitudinal, following a cohort of initially healthy people from 18 to 30 years ([@bibr35-2055102915612271], [@bibr36-2055102915612271]; [@bibr46-2055102915612271]).

The 14 studies examining the relationship between stress and progression of MS were all prospective; 12 of these were cohort studies ([@bibr1-2055102915612271], [@bibr2-2055102915612271]; [@bibr7-2055102915612271], [@bibr8-2055102915612271]; [@bibr9-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr31-2055102915612271], [@bibr32-2055102915612271]; [@bibr38-2055102915612271]; [@bibr44-2055102915612271]; [@bibr48-2055102915612271]) and 2 were case--control studies ([@bibr14-2055102915612271]; [@bibr52-2055102915612271]). The duration of these studies ranged from 28 weeks to 8 years, but in most it was about 1 year.

### Criteria for diagnosing MS and relapse {#section11-2055102915612271}

The criteria for the initial diagnosis of MS have evolved from those in [@bibr47-2055102915612271] publication, which were updated by [@bibr43-2055102915612271], and more recently by [@bibr25-2055102915612271], last reviewed by [@bibr42-2055102915612271].

The criteria for diagnosing relapse varied widely. Whereas some articles used biological criteria (new lesions on gadolinium-enhanced magnetic resonance imaging (MRI)) to determine disease progression ([@bibr31-2055102915612271], [@bibr32-2055102915612271]), most studies used clinical criteria to define relapse, either changes in Expanded Disability Status Scale score ([@bibr14-2055102915612271]; [@bibr31-2055102915612271]) or worsening or new symptoms ([@bibr1-2055102915612271], [@bibr2-2055102915612271]; [@bibr7-2055102915612271], [@bibr8-2055102915612271]; [@bibr9-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr38-2055102915612271]; [@bibr44-2055102915612271]; [@bibr52-2055102915612271]), with some variation in the definition of these concepts. Nevertheless, the most commonly used clinical criteria describe relapse as a worsening of the existing symptoms or appearance of new ones lasting more than 24 hours (labeled clinical criteria 5 in [Table 1](#table1-2055102915612271){ref-type="table"}) or more than 48 hours (labeled clinical criteria 6 in [Table 1](#table1-2055102915612271){ref-type="table"}) after at least 30 days of improvement or stability not associated with fever.

Regarding relapse criteria, we observed that studies that used biological criteria (new gadolinium-enhanced lesions) or changes in Expanded Disability Status Scale found a positive but not significant association (odds ratio (OR) = 2.3, 95% confidence interval (CI) = 0.9--5.6) between stress and MS ([@bibr14-2055102915612271]) or an association not sufficiently robust (OR = 1.64, 95% CI = 1.22--2.20) to predict clinical exacerbations ([@bibr31-2055102915612271]).

Methods used to evaluate stress and results: onset studies {#section12-2055102915612271}
----------------------------------------------------------

Two studies ([@bibr26-2055102915612271]; [@bibr45-2055102915612271]) used non-validated interviews; both found more emotional stress before onset (unspecific period of time), although in [@bibr45-2055102915612271] the difference was not significant (*χ*^2^ = 1.8, *p* \> .05).

Two other studies ([@bibr18-2055102915612271]; [@bibr51-2055102915612271]) used semi-structured interviews designed on the basis of previous information about stress; both showed a temporal relationship between greater emotional stress and MS. In the study by [@bibr18-2055102915612271], compared to matched controls without MS, more MS patients had experienced marked adversity in the year prior to onset of symptoms, (77% vs. 35% of controls; *χ*^2^ = 14.08, *p* \< .001). Similarly, [@bibr51-2055102915612271] found that MS patients had more unwanted stress than controls in the 2 years before onset (79% vs. 54%; *χ*^2^ = 12.93, *p* \< .001).

Two studies ([@bibr40-2055102915612271]; [@bibr46-2055102915612271]) used ad hoc questionnaires to determine the amount of stress. [@bibr40-2055102915612271] observed a nonsignificant trend toward more stressful events in MS patients than in patients with polyneuropathy (24.6% vs. 14.8%) in the year before onset. [@bibr46-2055102915612271] observed no effect of stress on MS development in 30 years' follow-up of a large cohort of initially healthy subjects.

One study used a rating scale of stressful events. [@bibr22-2055102915612271] found significant differences (*p* \< .01) between MS and controls in different symptoms related to stress such as mental health symptoms, negative life events, family problems, and social support.

Finally, two studies ([@bibr35-2055102915612271], [@bibr36-2055102915612271]) used data about specific stressful events from the National Multiple Sclerosis Registry and observed little evidence for a causal association between major stressful events and MS risk. Only parental divorce in childhood increased modestly the risk of MS ([@bibr36-2055102915612271]).

Methods used to evaluate stress and results: progression studies {#section13-2055102915612271}
----------------------------------------------------------------

Progression studies can be classified into two categories: those that evaluated the stress patients experienced in a period of time before a relapse retrospectively after the relapse occurred ([@bibr14-2055102915612271]; [@bibr52-2055102915612271]) and those that evaluated stress systematically before the relapse occurred ([@bibr1-2055102915612271], [@bibr2-2055102915612271]; [@bibr7-2055102915612271], [@bibr8-2055102915612271]; [@bibr9-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr31-2055102915612271], [@bibr32-2055102915612271]; [@bibr38-2055102915612271]; [@bibr44-2055102915612271]; [@bibr48-2055102915612271]).

In the first category, [@bibr52-2055102915612271] used a questionnaire and different scales and observed a significant positive relationship between stress and MS exacerbation: patients scoring 5 or above in Goldberg and Hillier's General Health Questionnaire-28 ([@bibr16-2055102915612271]) had a relative risk (RR) of exacerbation of 3.1 (95% CI). In contrast, [@bibr14-2055102915612271] used a structured interview to determine whether patients had undergone a single stressful event and found no differences between MS patients who had relapsed and those who had not, although cumulated stressful events were associated with a nonsignificantly higher risk of MS relapse (OR = 2.3, 95% CI = 0.9--5.6).

In the second category, eight studies used different combinations of questionnaires, scales, and interviews. [@bibr31-2055102915612271], [@bibr32-2055102915612271]) used different scales to evaluate stressful events and hassles monthly, considering the 8 weeks after every stressful event a period at risk for relapse; these studies found that *Conflict and disruption in routine* increased the odds of developing new gadolinium-enhanced lesions (OR = 1.64, 95% CI = 1.22--2.20, *p* \< .001), but was not robust enough to reliably predict clinical exacerbations. [@bibr38-2055102915612271] used a trimonthly questionnaire and observed no differences in stressful events between patients with or without subsequent relapses. [@bibr1-2055102915612271], [@bibr2-2055102915612271]) used a weekly questionnaire and a semi-structured interview at the beginning and end of the study. Both studies showed that stress was a potential trigger of MS exacerbations and vice versa; considering the 6 weeks after an stressful event as a period at risk for relapse, 85 percent of relapses were associated with an stressful event and 49 percent of stressful events were associated with relapses. [@bibr7-2055102915612271], [@bibr8-2055102915612271]) found similar results using the same semi-structured interview at the beginning and every 3 months, also confirming the bidirectional hypothesis.

[@bibr48-2055102915612271] using a self-reported stressful event scale every 6 months also found a bidirectional relationship between stress and MS exacerbation, in which MS progressed after stress and stress increased after MS exacerbations in a vicious cycle. More than one stressful event increased the risk of disease progression (OR = 1.13, *p* \< .001) and disease progression increased the risk of self-reported stress (OR = 2.13, *p* \< .001).

Finally, four studies ([@bibr9-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr44-2055102915612271]) used self-reported diaries. All these studies showed increased risk for exacerbation during the 4 weeks after a stressful event. [@bibr9-2055102915612271] found that one or more stressful events were associated with a 2-fold risk of relapse (RR = 2.2, 95% CI = 1.2--4.0, *p* \< .05), concluding that the increased risk of relapse was not "dose-dependent." In contrast, [@bibr27-2055102915612271] and [@bibr44-2055102915612271] found that cumulative stressful events (three or more) increased the risk of MS relapse (from OR = 5.36 to OR = 16.78, 95% CI).

Moderating and mediating factors: evaluation and results {#section14-2055102915612271}
--------------------------------------------------------

All but 2 of the 23 studies took into account potential modifying factors of the relationship between stress and MS ([Table 2](#table2-2055102915612271){ref-type="table"}). We classified these factors into three main categories: stressor properties, individual characteristics, and environmental factors.

###### 

Stress measuring instruments, moderator factors and results.

![](10.1177_2055102915612271-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/year                            Instruments used to measure stress                                                          Moderating mediating factors                                                  Instruments to measure moderating/mediating factors                                                                                            Results (1, stress--MS relationship; 2, moderating/mediating factors)
  -------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Papers measuring disease onset                                                                                                                                                                                                                                                                                                                                  

   [@bibr45-2055102915612271]            Non-validated interview (life story)                                                        Premorbid personality                                                         Allotting each patient in the personality schemes of Jung (extraversion--introversion) and Sheldon (viscerotonia, somatotonia, cerebrotonia)   \(1\) Emotional stress antedates onset or relapse but no significant differences between MS and controls (*χ*^2^ = 1.8, *p* \> .05).\
                                                                                                                                                                                                                                                                                                                                                                  (2) No specific premorbid personality type was defined in patients of MS.

   [@bibr26-2055102915612271]            Non-validated interview (life story)                                                        Stressor typology and duration                                                Classifying SLEs into:\                                                                                                                        \(1\) 28 of 32 patients reported data indicating the illness was preceded by an SLE.\
                                                                                                                                                                                                                   a) Sudden and transient\                                                                                                                       (2) Stressor duration is mainly sustained and protracted; stressor typology is indifferent.
                                                                                                                                                                                                                   b) Sudden and sustained\                                                                                                                       
                                                                                                                                                                                                                   c) Gradual and protracted                                                                                                                      

   [@bibr51-2055102915612271]            Interview based on a modified version of Holmes and Rahe Social Readjustment Rating Scale   Early life stress, coping style                                               Questions in the interview:\                                                                                                                   \(1\) There is a relationship between emotional stress and MS onset. More unwanted stress in MS patients (79%) than in controls (54%) (*χ*^2^ = 12.93, *p* \< .001).\
                                                                                                                                                                                                                   a) Emotional climate at home during childhood/adolescence\                                                                                     (2) Early life stress and coping style: no differences between MS patients and control group.
                                                                                                                                                                                                                   b) Assess how to react to life problems prior to onset age                                                                                     

   [@bibr18-2055102915612271]            Semi-structured interview\                                                                  Stressor severity, typology, and duration                                     Classifying SLEs into:\                                                                                                                        \(1\) Temporal relationship between marked adversity and MS symptoms (77% MS patients vs. 35% non-patients, *χ*^2^ = 14.08, *p* \< .001).\
                                         LEDS                                                                                                                                                                      a) Severely threatening events (punctual event + long-term \> 48 hours + very or moderately severe threat + self-focus)\                       (2) More marked life adversity (severely threatening events and marked difficulties) in MS patients 1 year before onset but most evident from 6 months to onset.
                                                                                                                                                                                                                   b) Marked difficulties (difficulty ⩾ 4 weeks + very, moderately, or severe threat)                                                             

   [@bibr40-2055102915612271]            Non-validated questionnaire modeled on DSM-IV                                               No                                                                                                                                                                                                                           No significant differences but more SLE in MS patients (24.6%) than in PNP patients (14.8%) the year before onset.

   [@bibr22-2055102915612271]            Questionnaire, once: LES                                                                    Personality, social support, and mental health symptoms                       Questionnaires, once:\                                                                                                                         \(1\) and (2) significant differences (*p* \< .01) were found between MS and control group in mental health symptoms, negative life events, family problems, and social support.\
                                                                                                                                                                                                                   Eysenck Personality Questionnaire\                                                                                                             Negative correlation of social support with negative emotions suggesting lack of ability in MS patients to use social support.
                                                                                                                                                                                                                   Social Support Reevaluate Scale\                                                                                                               
                                                                                                                                                                                                                   Symptom Check List 90                                                                                                                          

   [@bibr46-2055102915612271]            Questionnaire including questions on stress at home and work                                Early life stress                                                             Questionnaire including 22 questions on physical and sexual abuse in childhood and adolescence\                                                \(1\) No increased risk of MS associated with severe stress at home or work (HR 0.85 (95% CI) 0.32--2.26).\
                                                                                                                                                                                                                   Questions on physical abuse adapted from the Revised Conflict Tactics Scale                                                                    (2) Elevated but not significant risk among women having been forced into sexual activity several times during childhood (OR 1.51 (95% CI) 0.90--2.55) and adolescence (OR 1.25 (95% CI) 0.70--2.23).

   [@bibr35-2055102915612271]            Stressful life events:\                                                                     No                                                                                                                                                                                                                           No increased risk of MS in bereaved parents compared to those who did not lose a child. No increased risk in divorced or widowed persons compared with married persons.
                                         lose a child\                                                                                                                                                                                                                                                                                                            
                                         get divorced or widowed                                                                                                                                                                                                                                                                                                  

   [@bibr36-2055102915612271]            Stressful life events:\                                                                     Early life stress                                                             SLEs (until age 18 years):\                                                                                                                    \(1\) and (2) Persons exposed to any SLE in childhood were at 11% elevated risk for MS (RR 1.11 (95% CI) 1.03--1.20), compared to non-exposed persons.\
                                         parental divorce\                                                                                                                                                         parental divorce\                                                                                                                              Parental death and death of sibling were not associated. Persons exposed to parental divorce were at 13% increased risk (RR 1.13 (95% CI) 1.04--1.23).
                                         parental death\                                                                                                                                                           parental death\                                                                                                                                
                                         death of sibling                                                                                                                                                          death of sibling                                                                                                                               

  Papers measuring disease progression                                                                                                                                                                                                                                                                                                                            

   [@bibr52-2055102915612271]            Questionnaires:\                                                                            Coping style, stressor severity, and frequency                                Questionnaires:\                                                                                                                               \(1\) Relative risk of an exacerbation associated with a score of 5 or above in GHQ was 3.1 (95% CI), suggesting an emotional stress--exacerbation relationship.\
                                         Goldberg and Hillier's GHQ-28\                                                                                                                                            Ways of Coping Checklist\                                                                                                                      (2) Daily hassles: more severity in patients in exacerbation, no differences in frequency, suggesting that perceived impact is more important than number.\
                                         Hassles' Scale\                                                                                                                                                           Stressor intensity measured by Hassles Scale\                                                                                                  No significant differences in coping strategies, but patients in exacerbation who favored emotion-focused coping were consistently higher (*χ*^2^ = 8.4, *p* \< .01).
                                         Uplifts' Scales                                                                                                                                                           Stressor frequency is the number of SLEs in a 3-month period                                                                                   

   [@bibr14-2055102915612271]            Structured interview about SLEs                                                             Stressor frequency                                                            Number of SLEs in a period of 3 months                                                                                                         \(1\) No differences between groups for a single SLE.\
                                                                                                                                                                                                                                                                                                                                                                  (2) Cumulated SLEs were associated with higher risk of relapse but not significant (OR 2.3 (95% CI) 0.9--5.6).

   [@bibr48-2055102915612271]            Self-reported stressful events every 6 months following:\                                   Stressor frequency                                                            Number of SLEs (evaluated every 6 months)                                                                                                      \(1\) and (2) Increased risk of disease progression by level of stress (more than one SLE) (OR 1.13, *p* \< .001). Increased risk of reported stress by rate of disease progression (OR 2.13, *p* \< .001).\
                                         Holmes and Rahe checklist                                                                                                                                                                                                                                                                                                Vicious cycle "stress progression."

   [@bibr31-2055102915612271]            Questionnaires (monthly):\                                                                  Stressor frequency and typology                                               Number of SLEs (evaluated every 4 weeks)\                                                                                                      \(1\) and (2) *Conflict and disruption in routine* increased odds (OR 1.64 (95% CI) 1.22--2.20, *p* = .00083) of developing new MRI Gd+ lesions (8 weeks later).\
                                         Modified SRRS\                                                                                                                                                            Classification of typology:\                                                                                                                   Not sufficiently robust to predict clinical exacerbations reliability.
                                         Hassles Scale\                                                                                                                                                            a) Major negative events\                                                                                                                      
                                         Profile of Mood States                                                                                                                                                    b) Conflict and disruption in routine\                                                                                                         
                                                                                                                                                                                                                   c) Positive life events                                                                                                                        

   [@bibr1-2055102915612271]             Questionnaire, weekly:\                                                                     Stressor severity, duration, frequency, and source                            Classifying SLEs by severity:\                                                                                                                 \(1\) Stress is a potential trigger of exacerbations in patients with MS.\
                                         Psychiatric Epidemiologic Research Interview\                                                                                                                             a) Likert scale: *more severe* (1) to *less severe* (4)\                                                                                       85% of relapses were associated with an SLE and 49% of SLEs were associated with relapses in a 6-week time frame.\
                                         Semi-structured interview at the beginning/end of the study:\                                                                                                             Duration:\                                                                                                                                     (2) An increase in frequency of life events was associated with greater likelihood of MS exacerbations (HR 13.18 (95% CI) 1.67--104.39, *p* \< .05).
                                         LEDS                                                                                                                                                                      a) Short-term \<15 days\                                                                                                                       
                                                                                                                                                                                                                   b) Long-term ⩾ 15 days\                                                                                                                        
                                                                                                                                                                                                                   Source (different categories)\                                                                                                                 
                                                                                                                                                                                                                   Frequency (number of SLEs)                                                                                                                     

   [@bibr32-2055102915612271]            Questionnaire (monthly):\                                                                   Coping style                                                                  Coping with Health Injuries and Problems questionnaire                                                                                         \(1\) and (2) Modest support for that coping can moderate stress--MS relationship.\
                                         Modified Social Readjustment Rating Scale                                                                                                                                                                                                                                                                                Greater use of distraction (OR 0.69 (95% CI) 0.49--0.98, *p* = .037) and instrumental coping (OR 0.77 (95% CI) 0.57--1.04, *p* = .81) was marginally associated with decreased stress--MS relationship. Other coping forms did not.

   [@bibr2-2055102915612271]             Questionnaire, weekly:\                                                                     Cardiovascular reactivity, resting heart rate, and blood pressure             Measures on:\                                                                                                                                  \(1\) Stress is a potential trigger of relapse. They are more likely at-risk periods (6 weeks after SLE). Deteriorating cycle.\
                                         Psychiatric Epidemiologic Research Interview\                                                                                                                             cardiovascular reactivity to an acute experimental stressor (Stroop task)\                                                                     (2) Participants with higher cardiovascular reactivity to acute stress and higher baseline heart rate had a greater number of exacerbations (*r*(47) = 0.320, *p* \< .05) and weeks ill (*r*(47) = 0.350, *p* \< .05).
                                         Semi-structured interview at the end of the study:\                                                                                                                       resting heart rate\                                                                                                                            
                                         LEDS                                                                                                                                                                      blood pressure                                                                                                                                 

   [@bibr9-2055102915612271]             Self-reported weekly diaries of emotionally stressful events                                Stressor frequency                                                            Number of SLEs (evaluated weekly)                                                                                                              \(1\) At least one SLE is associated with double risk for relapse (RR 2.2 (95% CI) 1.2--4.0, *p* = .014) in a risk period (4 weeks). No differences in exacerbation risk after 1 or more SLE. Not dose dependent.

   [@bibr7-2055102915612271]             Semi-structured interview, at the beginning and every 3 months:\                            Stressor valence, typology, frequency, duration, and severity                 Classifying SLEs in typology:\                                                                                                                 \(1\) Bidirectional stress-illness hypothesis was confirmed.\
                                         LEDS                                                                                                                                                                      a) Emotional threat\                                                                                                                           (2) Acute events predicted greater relapse risk (\<6 months) than chronic difficulties (\>6 months).\
                                                                                                                                                                                                                   b) Goal frustration\                                                                                                                           The number of SLE is the most important property in relation to MS relapse risk.
                                                                                                                                                                                                                   Duration:\                                                                                                                                     
                                                                                                                                                                                                                   a) Acute events \<6 months\                                                                                                                    
                                                                                                                                                                                                                   b) Chronic difficulties \>6 months\                                                                                                            
                                                                                                                                                                                                                   Valence (positive, negative)\                                                                                                                  
                                                                                                                                                                                                                   Severity:\                                                                                                                                     
                                                                                                                                                                                                                   a) 4-point Likert scale: 0 (*mild or non-threatening*) to 4 (*severe*)\                                                                        
                                                                                                                                                                                                                   Number of SLEs                                                                                                                                 

   [@bibr8-2055102915612271]             Semi-structured interview, at the beginning and every 3 months:\                            Coping style, anxiety, depression, optimism, Health LOC, and Social Support   Questionnaires:\                                                                                                                               1 and 2) Exacerbation is predicted by acute stressor frequency counts and coping responses using social support but not by chronic stressors or other psychosocial factors.\
                                         LEDS                                                                                                                                                                      Beck Depression Inventory\                                                                                                                     Seeking social support decreases the relationship stress--relapse.
                                                                                                                                                                                                                   STAI---T\                                                                                                                                      
                                                                                                                                                                                                                   Ways of Coping\                                                                                                                                
                                                                                                                                                                                                                   Life Orientation Test\                                                                                                                         
                                                                                                                                                                                                                   MHLC\                                                                                                                                          
                                                                                                                                                                                                                   Sarason Social Support                                                                                                                         

   [@bibr27-2055102915612271]            Self-reported weekly diaries of emotionally stressful events                                Stressor duration, type, frequency, and severity                              Severity measure:\                                                                                                                             \(1\) Women with cumulative SLEs (3 or more) may be at greater risk for relapse during period at risk (4 weeks). For 3 SLEs (HR 5.36 (95% CI) 1.74--6.46, *p* = .003). For 4 SLEs (HR 16.78 (95% CI) 4.64--60.56, *p* \< .001).\
                                                                                                                                                                                                                   Recent Life Change Questionnaire\                                                                                                              (2) Duration is the only stressor property that seems to increase risk for relapse (HR 3 (95% CI) 1.01--9.13, *p* \< .05), but not stress type or severity.
                                                                                                                                                                                                                   Type of stress (six categories)\                                                                                                               
                                                                                                                                                                                                                   Duration (subjective measure):\                                                                                                                
                                                                                                                                                                                                                   Short-term\                                                                                                                                    
                                                                                                                                                                                                                   Long-term (10--14 days)\                                                                                                                       
                                                                                                                                                                                                                   Number of SLEs                                                                                                                                 

   [@bibr44-2055102915612271]            Self-reported weekly diaries of emotionally stressful events                                Anxiety\                                                                      Questionnaire, every 4 weeks:\                                                                                                                 \(1\) Three or more SLE increases in 6.7 times the risk of relapse in MS women (HR 6.7 (95% CI) 2.8--16.0, *p* \< .001).\
                                                                                                                                     stressor frequency                                                            Hamilton Rating Scale for Anxiety\                                                                                                             (2) High level of anxiety (score \>18 in HAM-A) is associated with 2.9 times the rate of relapse (HR 2.9 (95% CI) 1.3--6.4, *p* = .008) and with the number and severity of the SLE.
                                                                                                                                                                                                                   Number of SLEs (evaluated weekly)                                                                                                              

   [@bibr28-2055102915612271]            Self-reported weekly diaries of emotionally stressful events                                SSRI intake (escitalopram), stressor duration, and frequency                  Intake of escitalopram:\                                                                                                                       \(1\) and (2) Risk for relapse was 2.9 times higher in c-group (HR 2.9 (95% CI) 1.7--5.9, *p* \< .001), influenced only by long-term SLEs.\
                                                                                                                                                                                                                   10 mg/day\                                                                                                                                     In e-group only ⩾3 long-term SLEs were related to higher relapse risk.
                                                                                                                                                                                                                   Classifying duration:\                                                                                                                         
                                                                                                                                                                                                                   a) Short-term\                                                                                                                                 
                                                                                                                                                                                                                   b) Long-term (\>14 days)\                                                                                                                      
                                                                                                                                                                                                                   Number of SLEs                                                                                                                                 

   [@bibr38-2055102915612271]            Questionnaire, trimonthly: Paykel's checklist                                               Stressor severity and frequency                                               Severity measure:\                                                                                                                             \(1\) No differences in SLEs between patients with or without subsequent relapses.\
                                                                                                                                                                                                                   Subjective appraisal scoring SLE from 0 to 20\                                                                                                 (2) Number of stressors was the only factor which reached near significance in predicting relapses (*p* = .054).
                                                                                                                                                                                                                   Frequency measure:\                                                                                                                            
                                                                                                                                                                                                                   Number of SLE                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MS: multiple sclerosis; SLE: stressful life event, which produces emotional tension, different from everyday life; LEDS: Life Events and Difficulties Schedule; DSM-IV: *Diagnostic and Statistical Manual of Mental Disorders* (4th ed.); PNP: polyneuropathy; LES: Life Event Scale; HR: hazard ratio; CI: confidence interval; OR: odds ratio; RR: relative risk; GHQ: General Health Questionnaire; SRRS: Social Readjustment Rating Scale; MRI: magnetic resonance imaging; Gd+: gadolinium; LOC: Locus of Control; STAI-T: State Trait Anxiety Inventory - Trait; MHLC: Multidimensional Health Locus of Control Scale; SSRI: selective serotonin reuptake inhibitor (escitalopram).

### Stressors properties {#section15-2055102915612271}

Thirteen studies analyzed stressor properties such as type, duration, severity, valence, source, and frequency. Among the different stressor properties, type and source (for example, work stress) were the least significant ([@bibr1-2055102915612271]; [@bibr18-2055102915612271]; [@bibr26-2055102915612271]; [@bibr27-2055102915612271]). However, [@bibr31-2055102915612271] observed that only the type of stressor referred to as "Conflict and disruption in routine" was associated with new gadolinium-enhanced lesions. The duration of exposure to a stressor was more important. Stressors associated with relapses were mainly sustained and protracted or long-term stressors (versus acute stressors), lasting more than 48 hours ([@bibr1-2055102915612271]; [@bibr7-2055102915612271]; [@bibr18-2055102915612271]; [@bibr26-2055102915612271]). With regard to severity of the stressor, most studies found a stronger association with MS relapses for intermediate-to-severe intensity stressors ([@bibr1-2055102915612271]; [@bibr18-2055102915612271]; [@bibr52-2055102915612271]). Finally, frequency was important; in general, studies found that cumulated stress or the presence of various stressful events increased the risk of relapse compared with a single stressful event ([@bibr7-2055102915612271]; [@bibr14-2055102915612271]; [@bibr27-2055102915612271]; [@bibr38-2055102915612271]; [@bibr44-2055102915612271]; [@bibr48-2055102915612271]).

### Patients' characteristics {#section16-2055102915612271}

Eight studies evaluated the impact of different patient characteristics on the stress--MS relationship. Seven considered psychosocial factors such as premorbid personality ([@bibr45-2055102915612271]), coping style ([@bibr8-2055102915612271]; [@bibr32-2055102915612271]; [@bibr51-2055102915612271], [@bibr52-2055102915612271]), and mental health symptoms (anxiety, depression, optimism) ([@bibr8-2055102915612271]; [@bibr22-2055102915612271]; [@bibr44-2055102915612271]). Only one study ([@bibr2-2055102915612271]) evaluated biological factors (cardiovascular reactivity, resting heart rate, and blood pressure).

Personality did not seem to affect disease progression ([@bibr45-2055102915612271]), but other psychosocial factors differed significantly between MS patients and controls ([@bibr22-2055102915612271]), including a trend toward worse mental health in MS patients. In a recent study by [@bibr44-2055102915612271], a Hamilton Rating Scale for Anxiety ([@bibr19-2055102915612271]) score ⩾18 was associated with a hazard rate of 2.9 (95% CI = 1.3--6.4, *p* \< .05) for MS relapse.

There seems to be modest evidence that coping style affects MS; [@bibr32-2055102915612271] found greater use of distraction had a protective effect against MS (OR = 0.69, 95% CI = 0.49--0.98, *p* \< .05), but instrumental coping was only marginally associated with a decrease in the strength of the stress--MS relationship (OR = 0.77, 95% CI = 0.57--1.04, *p* \> .05). Other coping styles showed no effects on the relationship. [@bibr51-2055102915612271] neither found differences in coping styles between MS patients and controls but, in a more recent study of [@bibr52-2055102915612271] comparing MS patients in exacerbation with MS patients in remission, it was found that patients in exacerbation did use more emotional-focused strategies than those in remission, *χ*^2^ = 8.4, *p* \< .05.

Finally, [@bibr2-2055102915612271] found that higher cardiovascular reactivity to an acute stressor and higher baseline heart rate were significantly correlated with greater relapse rate (*r*(47) = .320, *p* \< .05) and longer illness after relapse (*r*(47) = .350, *p* \< .05).

### Environmental factors {#section17-2055102915612271}

Six studies examined environmental factors such as early life stress ([@bibr36-2055102915612271]; [@bibr46-2055102915612271]; [@bibr51-2055102915612271]), social support ([@bibr8-2055102915612271]; [@bibr40-2055102915612271]), or escitalopram intake ([@bibr28-2055102915612271]).

Regarding the early life stress, [@bibr46-2055102915612271] found a nonsignificant trend toward developing MS in women who had been forced into sexual activity several times during childhood (OR = 1.51, 95% CI = 0.90--2.55) or adolescence (OR = 1.25, 95% CI = 0.70--2.23). However, [@bibr36-2055102915612271] found that persons exposed to parental divorce in childhood were at 13 percent increased risk of developing MS (RR = 1.13, 95% CI = 1.04--1.023).

Finally, social support and intake of escitalopram seem to decrease the stress--relapse relationship. [@bibr22-2055102915612271] found a negative correlation between social support and negative emotions, suggesting that MS patients lacked the ability to use social support. [@bibr28-2055102915612271] studied the effects of escitalopram on stress-related relapses in a randomized controlled trial, finding that patients in the control group (no intake) had a risk of relapse 2.9 times higher than those in the experimental group (receiving escitalopram) (hazard ratio (HR) = 2.9, 95% CI = 1.7--5.9, *p* \< .001), but predicted only by long-term stressors (lasting more than 14 days).

Discussion {#section18-2055102915612271}
==========

To elucidate the relationship between stress and MS and moderating and mediating factors that might influence this relationship, we analyzed the results of 23 studies in function of the methods they used to evaluate stress. We classified studies into two main categories: those that analyzed the effect of stress on the onset of MS and those that analyzed the effect of stress on the progression of MS. Studies focused on onset used a retrospective design with interviews being the main instrument to assess stress. In these studies, semi-structured interviews and scales were the instruments that showed more significant associations with the onset of MS. Studies focused on progression were mostly prospective and evaluated stress systematically prior to exacerbations using a combination of interviews, questionnaires, scales, and self-reported diaries. Almost all these studies showed a significant positive relationship between stress and progression, and self-reported diaries yielded the most consistent results. The potential moderating and mediating factors with the most consistent effect on the stress--MS relationship were the duration, severity, and frequency of the stressor; anxiety, cardiovascular reactivity, and heart rate; and social support and escitalopram intake.

As previous reviews ([@bibr4-2055102915612271]; [@bibr33-2055102915612271]) pointed out, one of the main problems in evaluating the evidence for the relationship between stress and MS is the wide variety of methods used to measure stress. Moreover, different studies not only used different combinations of several stress-measuring instruments but also different study designs, temporal frameworks between stress and disease (onset or progression), and different criteria to evaluate disease onset and progression.

The studies that evaluated disease onset with a prospective design or ad hoc questionnaires failed to show a significant relationship between stress and disease onset. Only studies using interviews with a retrospective design or questionnaires and scales in a case--control design showed a significant relationship, although this approach cannot establish a causal link. To firmly confirm or rule out whether stress is a risk factor for MS onset, prospective studies that frequently assess stressors are required.

Most studies evaluating disease progression assessed stress prospectively before the changes in disease progression became evident. Almost all these studies showed a positive relationship, regardless of the instruments used or the temporal framework considered as the period "at risk" (from 4 to 8 weeks). However, the studies that used self-reported diaries or weekly assessment ([@bibr1-2055102915612271], [@bibr2-2055102915612271]; [@bibr9-2055102915612271]; [@bibr27-2055102915612271], [@bibr28-2055102915612271]; [@bibr44-2055102915612271]) had more consistent results. Another important element for obtaining consistent results is the criteria used to measure relapse. As mentioned by [@bibr30-2055102915612271], after a stressful life event, the changes in MS manifest in the following order: first, MRI brain lesions, second, clinical symptoms or relapses, and third, the changes in the Expanded Disability Status Scale. Therefore, studies using the Expanded Disability Status Scale to evaluate MS progression after stress would probably show less progression because the scores often do not change until long after patients notice worsening symptoms or several relapses have occurred. Thus, biological or clinical criteria, or a combination of the two, are likely to provide more accurate results in early stages. In addition, since stress can affect disease without causing relapse, but only worsening symptoms, it seems necessary to add periodic functionality assessment to evaluate different categories of health status.

The relationship between stress and disease is modulated by several factors. The characteristics of the stressors have been the most widely studied. Although one study (not included in the systematic review) found that psychosocial and occupational stress were linked to a disease worsening ([@bibr50-2055102915612271]), overall the typology and source of stress do not apparently moderate the stress--MS relationship. In contrast, stressor duration, severity, and frequency have consistently been identified as modifying factors.

Chronic stress, defined as exposure to a stressor for more than 48 hours, had a greater effect on MS than acute stress ([@bibr1-2055102915612271]; [@bibr7-2055102915612271], [@bibr8-2055102915612271]; [@bibr18-2055102915612271]; [@bibr26-2055102915612271]). However, the studies reviewed often categorized duration differently. For example, for [@bibr1-2055102915612271], long-term stressors were those lasting at least 15 days, but for [@bibr7-2055102915612271], [@bibr8-2055102915612271]), long-term stressors were those lasting more than 6 months. The effect of chronic stress on MS could be explained by alterations in the stress-response systems of the hypothalamic--pituitary--adrenal axis and autonomic nervous system (for a review, see [@bibr15-2055102915612271]).

Stressor severity is also important. Intermediate and severe stressors have shown the most consistent associations with disease progression. However, these results seem applicable only to everyday or common stress; in extremely stressing situations, such as war, relapse rate can decrease ([@bibr37-2055102915612271]). The frequency of exposure to stress is also positively associated with disease progression: an increase in the number of stressful events is associated with an increase in the likelihood of relapse. The reason why stressor duration, severity, and frequency consistently modify the effects of stress on MS but source and typology do not is that the former directly determine the amount of stress, whereas the latter depend on personal assessment.

Many studies have also explored the potential modifying role of patients' individual characteristics on the effects of stress on MS. The most important factors identified are anxiety, cardiovascular reactivity, and heart rate, all of which are related to autonomic reactivity. The autonomic nervous system is one of the stress-response systems and could be involved in MS pathogenesis and progression ([@bibr15-2055102915612271]). Future studies should take biological measures of stress into account, so they can analyze biological correlates of stressful situations. Biofeedback technology has been widely used to reduce stress and anxiety and might help teach people which emotional states cause greater activation of biological stress-response systems. In a recent review, [@bibr6-2055102915612271] concluded that biofeedback therapies are able to produce somatic peripheral changes (neuroendocrine and neurovegetative systems).

Another patient factor that has been analyzed is coping style; however, the results for this factor have been contradictory. Whereas [@bibr32-2055102915612271] found modest support for a moderating effect of coping style, [@bibr51-2055102915612271], [@bibr52-2055102915612271]) found no significant differences between MS patients and control group but a tendency to use a more emotion-focused coping style in MS patients experiencing exacerbations compared to patients in remission. [@bibr8-2055102915612271] found that only coping responses using social support had a modifying effect on stress. Other studies (not included in the systematic review) showed limited support for the stress-buffering effects of coping ([@bibr39-2055102915612271]) and a tendency for people with MS, especially men, to be less likely than the general population to adopt coping styles related to problem-solving and seeking social support ([@bibr24-2055102915612271]). More research is needed to elucidate the effects of coping on stress.

Finally, the environmental factors escitalopram intake and social support decrease the effect of stress on MS ([@bibr8-2055102915612271]; [@bibr28-2055102915612271]). Escitalopram reduces the stress-dependent relapse rate in MS patients ([@bibr28-2055102915612271]). Escitalopram regulates serotonin reuptake and blunts autonomic reactivity, resulting in lower emotional reactivity to stressful situations ([@bibr13-2055102915612271]). The efficacy of escitalopram in reducing the relapse rate in [@bibr28-2055102915612271] clinical trial opens new directions for the study of MS. It could be interesting to study whether disease progression is linked to genetic factors related to serotonin transporters due to that serotoninergic neurotransmission in MS patients is altered in limbic and paralimbic regions as well as in the frontal cortex ([@bibr20-2055102915612271]).

Social support can attenuate responses to stress or threatening situations by reducing neural activity in regions that respond to basic survival threats while increasing activity in regions that process safety signals ([@bibr12-2055102915612271]). Other studies in MS patients have found that social support may moderate the impact of negative life events and have a positive effect on quality of life ([@bibr11-2055102915612271]) and that it is a predictor of perceived health status ([@bibr21-2055102915612271]).

Although our systematic review showed little evidence for early life stress as a moderating factor, a recent case--control study ([@bibr49-2055102915612271]) found that MS patients had more traumatic experiences in childhood and adolescence than healthy people. Moreover, patients with early life stress showed a higher relapse rate than those without. Early life stress can cause neuroendocrine alterations that remain into adulthood, increasing susceptibility to certain diseases ([@bibr41-2055102915612271]) and increasing the prevalence of severe psychological disorders ([@bibr3-2055102915612271]) that predispose to inadequate coping in stressful situations. More prospective studies are needed to better understand the effect of early life stress in MS.

Our study has both strengths and limitations. To our knowledge, this is the first review of studies analyzing the relationship between stress and MS that takes into account how stress was evaluated and moderators of the stress--MS relationship. Although the first article included in our review dates from 1950, we searched three important databases compiling publications from 1900 to the present in an attempt to summarize all the evidence accumulated since Charcot first described MS in [@bibr10-2055102915612271]. Moreover, we took into account English and Spanish languages, more comprehensive search than other papers. However, relatively few studies met the inclusion criteria. We did not include stress-intervention or animal studies, although these studies could surely contribute important data about the stress--MS relationship. Almost all the studies took at least one moderating factor into consideration; however, the wide variety of factors considered meant that few studies considered the same factors, precluding strong conclusions about the impact of most moderating and mediating factors. Almost all the studies reviewed were done in women, so despite the higher prevalence of MS in women, the results extracted may not be generalizable to the entire population.

Conclusion {#section19-2055102915612271}
==========

The effect of stress on the onset of MS remains unclear. More prospective studies evaluating stress systematically are needed to better understand this effect. In stress progression studies, instruments and designs based on self-evaluation and subjective measures have shown more consistent results than objective ones or instruments based on standard stressors. This means that patients' subjective appraisal of the stress could be an important predictor of MS relapse and onset. Also, the criteria used to evaluate disease progression are important in the evaluation of results. The greatest amplifying or buffering effects on stress come from factors directly related to the amount of stress and autonomicnervous system reactivity. Future studies should clarify the biological mechanisms involved: combining self-reported measures with biofeedback technology and genetic evaluation can improve our knowledge about the relationships between stress and MS. We also strongly recommend including moderating factors in studies on the effects of stress on MS; this approach can provide information that might be useful for treating patients, since some factors such as anxiety and coping styles are potentially modifiable.
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